INVIZYNE TECHNOLOGIES INC (IZTC) Stock Fundamental Analysis

NASDAQ:IZTC • US4618741098

16.5 USD
+1 (+6.45%)
Last: Feb 11, 2025, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to IZTC. IZTC was compared to 521 industry peers in the Biotechnology industry. IZTC has a bad profitability rating. Also its financial health evaluation is rather negative. IZTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IZTC has reported negative net income.
IZTC Yearly Net Income VS EBIT VS OCF VS FCFIZTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -500K -1M -1.5M -2M

1.2 Ratios

  • IZTC has a Return On Assets (-57.25%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.25%
ROE N/A
ROIC N/A
ROA(3y)-53.6%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IZTC Yearly ROA, ROE, ROICIZTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IZTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IZTC Yearly Profit, Operating, Gross MarginsIZTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • IZTC has about the same amout of shares outstanding than it did 1 year ago.
  • IZTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IZTC Yearly Shares OutstandingIZTC Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2M 4M 6M 8M
IZTC Yearly Total Debt VS Total AssetsIZTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 1M 2M 3M

2.2 Solvency

  • IZTC has an Altman-Z score of 4.12. This indicates that IZTC is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.12, IZTC is doing good in the industry, outperforming 78.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 4.12
ROIC/WACCN/A
WACCN/A
IZTC Yearly LT Debt VS Equity VS FCFIZTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 1M -1M -2M

2.3 Liquidity

  • IZTC has a Current Ratio of 0.25. This is a bad value and indicates that IZTC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.25, IZTC is not doing good in the industry: 96.45% of the companies in the same industry are doing better.
  • IZTC has a Quick Ratio of 0.25. This is a bad value and indicates that IZTC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IZTC has a Quick ratio of 0.25. This is amonst the worse of the industry: IZTC underperforms 96.27% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
IZTC Yearly Current Assets VS Current LiabilitesIZTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • IZTC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.01%.
EPS 1Y (TTM)-46.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IZTC. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IZTC Price Earnings VS Forward Price EarningsIZTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IZTC Per share dataIZTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IZTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

INVIZYNE TECHNOLOGIES INC

NASDAQ:IZTC (2/11/2025, 8:00:02 PM)

16.5

+1 (+6.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners1.21%
Inst Owner Change2.37%
Ins Owners27.99%
Ins Owner Change0%
Market Cap134.15M
Revenue(TTM)N/A
Net Income(TTM)-2.04M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -57.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.6%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z 4.12
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)327.93%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.06%
OCF growth 3YN/A
OCF growth 5YN/A

INVIZYNE TECHNOLOGIES INC / IZTC FAQ

What is the fundamental rating for IZTC stock?

ChartMill assigns a fundamental rating of 1 / 10 to IZTC.


Can you provide the valuation status for INVIZYNE TECHNOLOGIES INC?

ChartMill assigns a valuation rating of 0 / 10 to INVIZYNE TECHNOLOGIES INC (IZTC). This can be considered as Overvalued.


What is the profitability of IZTC stock?

INVIZYNE TECHNOLOGIES INC (IZTC) has a profitability rating of 0 / 10.